KORU Medical Systems, Inc. — FY2023 Form 10-K
Business context and reporting period. This is an annual report for the fiscal year ended December 31, 2023, not a standalone fourth-quarter report. KORU develops and sells large-volume subcutaneous infusion systems, primarily for immunoglobulin therapies. Revenue comes from domestic core, international core and novel therapies, including product sales and engineering services for biopharmaceutical programs.
Key financial results
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue | $28.52 million | $27.90 million |
| Gross profit / margin | $16.71 million / 58.6% | $15.37 million / 55.1% |
| Operating expenses | $26.98 million | $26.15 million |
| Operating loss | $10.27 million | $10.78 million |
| Net loss | $13.74 million; $0.30 per share | $8.66 million; $0.19 per share |
| Cash used in operating activities | $4.89 million | $5.40 million |
| Cash and cash equivalents at year-end | $11.48 million | $17.41 million |
- Revenue mix: Domestic core revenue grew 5.9% to $22.45 million; international core grew 10.4% to $4.60 million. Novel therapies revenue fell 41.6% to $1.48 million.
- Profitability: Gross margin improved by 3.5 percentage points, which management attributed mainly to manufacturing productivity and product mix. Operating loss narrowed, but net loss increased because of a $6.0 million allowance against deferred tax assets; the allowance contributed to a $4.0 million income tax expense.
- Cash flow and investment: Investing cash outflow was $0.81 million, principally for equipment. Financing cash outflow was $0.22 million. Cash declined by $5.93 million during the year. Inventory fell to $3.48 million from $6.40 million.
- Liquidity and obligations: Current assets were $20.26 million and current liabilities were $4.45 million at year-end. The balance sheet reported a $0.31 million note payable and $0.43 million of finance lease liabilities, as well as $3.70 million of operating lease liabilities. In March 2024, KORU entered into a $5 million revolving facility and a $5 million term-loan facility; no borrowings were outstanding as of March 13, 2024.
Material changes and management outlook
- Revenue increased 2.2% overall: growth in core markets was partly offset by lower novel-therapy engineering revenue and fewer clinical-trial supply shipments.
- Research and development expense rose 15.9% to $5.74 million. The company expects further R&D investment over the next 12 months to support completion of a next-generation pump and consumable system.
- Management said cash and operating cash flows should meet requirements for at least the next 12 months. It also cautioned that longer-term plans may require drawing on the new credit facility, additional debt, equity financing, or a combination; financing availability is not assured. The filing provides no specific 2024 revenue or earnings guidance.
- In March 2024, EU notified body BSI reported that it could not recommend continued certification after reviewing technical documentation related to a prior audit nonconformance. KORU appealed. If unsuccessful, certification could be suspended for some or all products, potentially affecting EU revenue. Management expects the appeal to limit any impact, but that outcome is uncertain.
Risks, contingencies and unusual items
- Customer concentration: Five distributors represented approximately 74% of net revenue; one U.S. distributor represented approximately 41%. Three major distributors accounted for approximately 66% of net product revenue.
- Supply and manufacturing: Most components are single-sourced. Command Medical Products supplies subassemblies and manufactures most consumables; disruption or difficulty qualifying replacement suppliers could constrain production. The filing also notes civil unrest in Nicaragua, where products are assembled and packaged.
- Regulatory exposure: EU MDR compliance will require investment, with the stated transition deadline for relevant Class IIa products extending to December 2028, subject to certification requirements. UKCA requirements also affect continued sales in Great Britain.
- Market and execution risks: Results depend on availability and demand for drugs delivered by KORU’s systems, reimbursement, competition, new-product development and biopharmaceutical programs that may be delayed, discontinued or fail to gain acceptance.
- Tax and financing: The deferred-tax valuation allowance is a material estimate and was identified as a critical audit matter. The new credit facilities are secured by substantially all company assets and include a monthly minimum adjusted quick-ratio covenant.
- The company reported no material legal proceeding. Management concluded disclosure controls and internal control over financial reporting were effective as of year-end; the independent auditor did not provide an attestation on internal control.
Important facts for investors to verify
- Progress and outcome of the BSI appeal, and any resulting restrictions on EU product certification or revenue.
- Whether core-market growth can continue and offset weaker novel-therapy revenue, including the timing and commercial prospects of the next-generation system.
- Cash burn, working-capital needs and the assumptions behind management’s statement that liquidity is adequate for at least 12 months.
- Credit-facility borrowing terms, covenant headroom, collateral implications and any subsequent borrowing or equity issuance.
- Distributor concentration and contingency plans for disruption at Command or other single-source suppliers.
- Support for deferred-tax-asset realizability and any future change to the $6.0 million valuation allowance.